Reed Jobs would rather talk about curing cancer than his famous last name, according to TechCrunch, which recently checked back in with the founder of the biotech venture firm Yosemite.
A lot has changed since TechCrunch last sat down with Jobs at its Disrupt conference nearly three years ago. Back then, Yosemite was brand new and the broader biotech sector was still reeling from a post-pandemic crash, according to the same report.
Today, TechCrunch says the firm has grown into a team of 17. The timing is notable: the report points to a cluster of blockbuster drugs that are all set to lose patent protection at roughly the same moment, a shift that tends to reshape which treatments get funded and developed next.
Jobs, the son of Apple co-founder Steve Jobs, has positioned Yosemite around cancer research, and TechCrunch frames his focus as squarely on the science rather than his surname. The interview does not provide additional financial figures or specific drug details beyond these points.
Why it matters: when patents on major drugs expire around the same time, the door opens for new players and new approaches — and a well-funded venture firm aiming squarely at cancer could help decide which of those next-generation treatments actually reach patients.